The progression of cardiometabolic disease: Validation of a new cardiometabolic disease staging system applicable to obesity

• DOI: 10.1002/oby.20585
• Publication Date: 2013-07-27T05:56:38Z
• Authors: Fangjian Guo; Douglas R. Moelle...; W. Timothy Garvey
• Keywords: Impaired fasting glucose; Cumulative incidence

To validate a Cardiometabolic Disease Staging (CMDS) system for assigning risk level diabetes, and all-cause cardiovascular disease (CVD) mortality.Two large national cohorts, CARDIA NHANES III, were used to CMDS. CMDS: Stage 0: metabolically healthy; 1: one or two metabolic syndrome factors [other than impaired fasting glucose (IFG)]; 2: IFG tolerance (IGT) (without IFG); 3: of three (IFG, IGT, and/or syndrome); 4: type 2 diabetes mellitus/CVD.In the study, compared with 0 healthy subjects, adjusted exponentially increased from 1 [hazard ratio (HR) 2.83, 95% confidence interval (CI): 1.76-4.55], (HR 8.06, CI 4.91-13.2), 3 23.5, 13.7-40.1) (P trend <0.001). In both cumulative incidence multivariable HRs markedly CVD mortality advancement stage Stages 4. Adjustment body mass index (BMI) minimally affected risks all-cause/CVD using CMDS.CMDS can discriminate wide range mortality, independent BMI, should be studied as assessment tool guide interventions that prevent treat cardiometabolic disease.